TNFRSF10B and neoplasm: Receptor 1 (DR4) and receptor 2 (DR5) of tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) are highly expressed on most tumor cells and thus present an ideal target for active targeting therapy [25–27].